Currently, rilotumumab is no longer under investigation in CRC, even if it could be proposed in selected MET positive tumors independently on KRAS status; we are waiting results of a recently completed phase II randomized study of the anti-MET antibody, onartuzumab, in association with standard first-line chemotherapy in CRC patients [63]. The gene discussed is KRAS; the disease is colorectal carcinoma.